As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AI-powered generative agents could revolutionize public health policymaking. By fine-tuning these simulations, governments ...

UK company Prokarium has raised $10 million to develop groundbreaking synthetic biology techniques to create a new generation of vaccines, which could be taken orally, and not have to be kept in a ...

The company’s proprietary Digital Immune Optimized Synthetic Vaccine (DIOSynVax) platform uses artificial intelligence to create safer and stronger vaccines for today and smarter for tomorrow.

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the company ...

Peptide-based vaccines deliver tumor-specific antigens to dendritic cells (DCs), triggering tumor-targeted T-cell responses. A peptide-peptide conjugate technology previously developed by researchers ...